Podium to Practice: EHA 2026 – Leukemia: ASC4FIRST WK 144

Podium to Practice: EHA 2026 – Leukemia: ASC4FIRST WK 144

Podium to Practice: EHA 2026

Studies / Trials Discussed

S160 – ASC4FIRST WK 144 ANALYSIS: CONTINUED SUPERIOR EFFICACY AND FAVORABLE SAFETY OF ASCIMINIB VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

Icon Chair Speaker

Chair

Dr. Brett Houston

Icon Chair Speaker

Speakers

Dr. Christopher Hillis

Dr. Sonia Cerquozzi

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

S160 – ASC4FIRST WK 144 ANALYSIS: CONTINUED SUPERIOR EFFICACY AND FAVORABLE SAFETY OF ASCIMINIB VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
Tagged